Equities Analysts Offer Predictions for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Equities researchers at HC Wainwright cut their Q1 2026 earnings estimates for Iovance Biotherapeutics in a report released on Wednesday, April 22nd. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn ($0.22) per share for the quarter, down from their previous forecast of ($0.15). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.77) EPS and FY2027 earnings at ($0.57) EPS.

Several other brokerages also recently commented on IOVA. Barclays upped their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. UBS Group upped their price objective on shares of Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Thursday, March 5th. Chardan Capital reaffirmed a “buy” rating and set a $16.00 price objective on shares of Iovance Biotherapeutics in a research note on Friday, April 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Monday, April 6th. Finally, Truist Financial raised shares of Iovance Biotherapeutics to a “hold” rating in a research note on Wednesday, March 25th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.88.

Iovance Biotherapeutics Stock Down 1.4%

NASDAQ IOVA opened at $3.48 on Friday. The company has a 50-day simple moving average of $3.70 and a two-hundred day simple moving average of $2.85. Iovance Biotherapeutics has a 12-month low of $1.64 and a 12-month high of $5.63. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -3.11 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The business had revenue of $86.77 million during the quarter, compared to analyst estimates of $81.61 million.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock valued at $74,275,000 after purchasing an additional 3,148,096 shares during the last quarter. State Street Corp lifted its holdings in shares of Iovance Biotherapeutics by 51.5% during the fourth quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock valued at $55,041,000 after purchasing an additional 6,851,486 shares during the last quarter. Invenomic Capital Management LP increased its position in Iovance Biotherapeutics by 13.5% during the 4th quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock valued at $32,649,000 after buying an additional 1,417,897 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Iovance Biotherapeutics by 30.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock valued at $23,499,000 after buying an additional 2,032,062 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Iovance Biotherapeutics by 16.4% during the fourth quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock valued at $21,821,000 after buying an additional 1,123,337 shares during the last quarter. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.